Norden Group LLC Sells 792 Shares of Zoetis Inc. (NYSE:ZTS)

Norden Group LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,469 shares of the company’s stock after selling 792 shares during the period. Norden Group LLC’s holdings in Zoetis were worth $1,277,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Blue Bell Private Wealth Management LLC raised its stake in shares of Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after purchasing an additional 89 shares in the last quarter. Independence Bank of Kentucky raised its stake in shares of Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Ramirez Asset Management Inc. bought a new stake in Zoetis in the 3rd quarter valued at $35,000. First Financial Corp IN raised its stake in Zoetis by 57.2% in the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock valued at $43,000 after acquiring an additional 79 shares during the period. Finally, FinTrust Capital Advisors LLC raised its stake in Zoetis by 42.1% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock valued at $45,000 after acquiring an additional 77 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS traded up $0.48 during trading hours on Tuesday, hitting $160.18. 1,923,902 shares of the company were exchanged, compared to its average volume of 3,125,759. The firm’s fifty day moving average is $171.21 and its 200 day moving average is $179.23. The company has a market cap of $73.26 billion, a price-to-earnings ratio of 31.60, a P/E/G ratio of 2.42 and a beta of 0.85. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the business earned $1.15 earnings per share. On average, equities analysts anticipate that Zoetis Inc. will post 5.79 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.08%. Zoetis’s dividend payout ratio is presently 34.12%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research analyst reports. Stifel Nicolaus dropped their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday. The Goldman Sachs Group increased their price target on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Piper Sandler restated an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Barclays dropped their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Finally, StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $216.13.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the transaction, the executive vice president now directly owns 20,417 shares in the company, valued at $4,037,257.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 2,209 shares of company stock worth $371,293. 0.16% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.